IQVIA (IQV) Stock Forecast & Price Target $167.87 -3.63 (-2.12%) Closing price 03:59 PM EasternExtended Trading$168.02 +0.15 (+0.09%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IQVIA - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating BuyBased on 17 Analyst RatingsSell0Hold2Buy15 Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Buy." Out of the 17 analysts, 2 have given a hold rating, 13 have given a buy rating, and 2 have given a strong buy rating for IQV. Consensus Price Target $225.6934.44% Upside According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $225.69. The highest price target for IQV is $258.00, while the lowest price target for IQV is $185.00. The average price target represents a forecasted upside of 34.44% from the current price of $167.87. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for IQV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IQV Analyst Ratings Over TimeTypeCurrent Forecast5/21/25 to 5/21/261 Month Ago4/21/25 to 4/21/263 Months Ago2/20/25 to 2/20/261 Year Ago5/21/24 to 5/21/25Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)Buy13 Buy rating(s)13 Buy rating(s)10 Buy rating(s)16 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)4 Hold rating(s)6 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$225.69$226.63$235.20$228.14Forecasted Upside34.44% Upside28.91% Upside42.01% Upside66.12% UpsideConsensus RatingBuyBuyModerate BuyModerate Buy IQV Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History IQV Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table IQVIA Stock vs. The CompetitionTypeIQVIAMedical CompaniesBroader MarketConsensus Rating Score 3.00 2.29 2.52Consensus RatingBuyHoldModerate BuyPredicted Upside34.44% Upside1,714.69% Upside15.95% UpsideNews Sentiment RatingNeutral NewsSee Recent IQV NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/7/2026 Morgan Stanley3 of 5 stars Set Target$225.00+25.57%5/4/2026 Weiss RatingsNot Rated DowngradeHold (C) ➝ Hold (C-)4/8/2026 Evercore4 of 5 starsElizabeth AndersonNot RatedReiterated RatingOutperform$185.00+10.93%3/9/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCharles RhyeeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy$174.00 ➝ $213.00+22.02%3/6/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLuke SergottSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$210.00+17.65%3/3/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRyan HalstedSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$221.00+26.66%2/23/2026 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$215.00+32.20%2/19/2026 Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJailendra SinghSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$290.00 ➝ $245.00+48.73%2/6/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDan LeonardSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$280.00 ➝ $240.00+30.09%2/6/2026 BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSean DodgeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$250.00+34.06% Get the Latest News and Ratings for IQV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter. 2/6/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingShlomo RosenbaumSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$273.00 ➝ $220.00+19.25%2/6/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCasey WoodringSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$255.00 ➝ $225.00+20.00%2/6/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid WindleySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$270.00 ➝ $255.00+36.01%2/6/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPatrick DonnellySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$230.00 ➝ $200.00+6.68%10/29/2025 Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric ColdwellSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetNeutral ➝ Outperform$224.00 ➝ $258.00+18.21%10/9/2025 HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRajesh KumarSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy$195.00 ➝ $235.00+17.15%9/3/2025 Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJamie ClarkSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$214.00+17.92%7/23/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform2/3/2025 BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid LarsenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral12/20/2024 StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJeff GarroSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight$250.00+30.53%12/13/2024 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$255.00 ➝ $235.00+17.54%11/19/2024 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform$260.00 ➝ $248.00+28.58%11/1/2024 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$270.00 ➝ $265.00+27.09%11/1/2024 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$280.00 ➝ $250.00+20.00%7/31/2024 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid ToungSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-BuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:29 AM ET. Should I Buy IQVIA Stock? IQV Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, May 17, 2026. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com. IQVIA Bull Case Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.: The current stock price is around $178, which may present a buying opportunity for investors looking for growth in the life sciences sector. IQVIA Holdings Inc. has demonstrated strong financial performance, reporting a revenue increase of over 8% compared to the same quarter last year, indicating robust demand for its services. The company has a solid return on equity of 30.50%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns. Analysts have a consensus price target of approximately $225.69, indicating potential upside from the current stock price, which could attract investors looking for capital appreciation. IQVIA has initiated a share repurchase program worth $2 billion, signaling confidence from management in the company's valuation and providing a potential boost to shareholder value. IQVIA Bear Case Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons: The company has a relatively high debt-to-equity ratio of 2.20, which may raise concerns about financial leverage and the ability to manage debt obligations effectively. Despite recent revenue growth, the stock has shown volatility, with a beta of 1.18, indicating that it may be more sensitive to market fluctuations, which could pose risks for conservative investors. Some analysts have recently adjusted their price targets downward, reflecting a cautious outlook on the stock's near-term performance, which could deter potential investors. The current market cap of approximately $29.79 billion may limit growth potential compared to smaller, more agile competitors in the life sciences industry. With a price-to-earnings ratio of 22.12, the stock may be considered overvalued by some investors, especially if earnings growth does not meet expectations. IQV Forecast - Frequently Asked Questions What is IQVIA's forecast for 2026? According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $225.69, with a high forecast of $258.00 and a low forecast of $185.00. Should I buy or sell IQVIA stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 2 hold ratings, 13 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IQV shares. Does IQVIA's stock price have much upside? According to analysts, IQVIA's stock has a predicted upside of 34.44% based on their 12-month stock forecasts. Has IQVIA been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, IQVIA's stock had 2 upgrades and 1 downgrade by analysts. What analysts cover IQVIA? IQVIA has been rated by research analysts at Barclays, Evercore, Mizuho, Morgan Stanley, Royal Bank Of Canada, TD Cowen, and Weiss Ratings in the past 90 days. Do Wall Street analysts like IQVIA more than its competitors? Analysts like IQVIA more than other "medical" companies. The consensus rating for IQVIA is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IQV compares to other companies. Stock Forecasts and Research Tools Related Companies BRKR Stock Forecast ICLR Stock Forecast MEDP Stock Forecast TECH Stock Forecast A Stock Forecast CRL Stock Forecast DHR Stock Forecast MTD Stock Forecast RVTY Stock Forecast TMO Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With IQVIA RecommendationsMorgan StanleyWeiss RatingsWall Street ZenEvercoreTD CowenBarclaysRoyal Bank Of CanadaMizuhoTruist FinancialUBS GroupCitigroupBMO Capital MarketsJPMorgan Chase & Co.Jefferies Financial GroupStifel Nicolaus This page (NYSE:IQV) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
